Skip to main content

Table 4 Healthcare costs averted

From: Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19

 

Hospitalizations

ICU

MV

Total

All Variants

Status Quo

$12,893,208,444

$3,080,307,586

$1,752,408,802

$17,725,924,832

Oral Vaccine Scenario 1

$10,029,809,055

$2,406,683,835

$1,370,556,923

$13,807,049,813

Averted Scenario 1

$2,863,399,389

$673,623,751

$381,851,879

$3,918,875,019

Oral Vaccine Scenario 2

$9,468,415,443

$2,272,703,270

$1,294,364,405

$13,035,483,118

Averted Scenario 2

$3,424,793,001

$807,604,316

$458,044,397

$4,690,441,714

Omicron

Status Quo

$10,522,771,115

$2,373,340,366

$1,340,682,366

$14,236,793,848

Oral Vaccine Scenario 1

$8,103,110,685

$1,831,495,124

$1,035,716,597

$10,970,322,405

Averted Scenario 1

$2,419,660,431

$541,845,242

$304,965,770

$3,266,471,443

Oral Vaccine Scenario 2

$7,643,815,500

$1,727,960,169

$977,257,337

$10,349,033,006

Averted Scenario 2

$2,878,955,615

$645,380,197

$363,425,030

$3,887,760,841